Future Perspectives and Unmet Needs in Renal Cell Carcinoma
The expert panel provides key takeaways and closing thoughts on future perspectives and unmet needs in the treatment of renal cell carcinoma.
Stay updated with breaking news from Renal Cell. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The expert panel provides key takeaways and closing thoughts on future perspectives and unmet needs in the treatment of renal cell carcinoma.
The defendant approached WIT to provide an expert who could help bring their drug to market and invalidate the claims of the plaintiff.
First presentation of results from Phase 3 CheckMate -67T trial with subcutaneous formulation of Opdivo to be shared in a late-breaking oral presentation Four-year data from CheckMate -9ER and...
– Phase 1b/2 clinical trial expected to begin enrolling patients before year-end 2023 – ...
– Results for Exelixis’ next-generation tyrosine kinase inhibitor demonstrated an objective response rate of 38% and a disease control rate of 88% – – Anti-tumor activity was observed in...